384 related articles for article (PubMed ID: 26840338)
41. Reduced Hypoglycemia Risk in Type 2 Diabetes Patients Switched to/Initiating Insulin Glargine 300 vs 100 U/ml: A European Real-World Study.
Escalada J; Bonnet F; Wu J; Bonnemaire M; Gupta S; Cambron-Mellott JM; Nicholls C; Müller-Wieland D
Adv Ther; 2020 Sep; 37(9):3863-3877. PubMed ID: 32681460
[TBL] [Abstract][Full Text] [Related]
42. Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: The DURATION-7 randomized study.
Guja C; Frías JP; Somogyi A; Jabbour S; Wang H; Hardy E; Rosenstock J
Diabetes Obes Metab; 2018 Jul; 20(7):1602-1614. PubMed ID: 29473704
[TBL] [Abstract][Full Text] [Related]
43. Modulation of insulin dose titration using a hypoglycaemia-sensitive algorithm: insulin glargine versus neutral protamine Hagedorn insulin in insulin-naïve people with type 2 diabetes.
Home PD; Bolli GB; Mathieu C; Deerochanawong C; Landgraf W; Candelas C; Pilorget V; Dain MP; Riddle MC
Diabetes Obes Metab; 2015 Jan; 17(1):15-22. PubMed ID: 24957785
[TBL] [Abstract][Full Text] [Related]
44. Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Lixisenatide and Insulin Glargine, Versus Insulin Glargine in Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy: The LixiLan Proof-of-Concept Randomized Trial.
Rosenstock J; Diamant M; Aroda VR; Silvestre L; Souhami E; Zhou T; Perfetti R; Fonseca V;
Diabetes Care; 2016 Sep; 39(9):1579-86. PubMed ID: 27284114
[TBL] [Abstract][Full Text] [Related]
45. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).
Home PD; Bergenstal RM; Bolli GB; Ziemen M; Rojeski M; Espinasse M; Riddle MC
Diabetes Care; 2015 Dec; 38(12):2217-25. PubMed ID: 26084341
[TBL] [Abstract][Full Text] [Related]
46. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
Zhang B; Zhao J; Yang W;
Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
[TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
48. Improved treatment satisfaction in patients with type 1 diabetes treated with insulin glargine 100U/mL versus neutral protamine Hagedorn insulin: An exploration of key predictors from two randomized controlled trials.
Polonsky W; Traylor L; Gao L; Wei W; Ameer B; Stuhr A; Vlajnic A
J Diabetes Complications; 2017 Mar; 31(3):562-568. PubMed ID: 28040350
[TBL] [Abstract][Full Text] [Related]
49. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
[TBL] [Abstract][Full Text] [Related]
50. Effect of basal insulin dosage on blood glucose concentration in ambulatory surgery patients with type 2 diabetes.
Demma LJ; Carlson KT; Duggan EW; Morrow JG; Umpierrez G
J Clin Anesth; 2017 Feb; 36():184-188. PubMed ID: 28183563
[TBL] [Abstract][Full Text] [Related]
51. Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus.
Freemantle N; Mauricio D; Giaccari A; Bailey T; Roussel R; Franco D; Berthou B; Pilorget V; Westerbacka J; Bosnyak Z; Bonnemaire M; Cali AMG; Nguyên-Pascal ML; Penfornis A; Perez-Maraver M; Seufert J; Sullivan SD; Wilding J; Wysham C; Davies M
Curr Med Res Opin; 2020 Apr; 36(4):571-581. PubMed ID: 31865758
[No Abstract] [Full Text] [Related]
52. Hypoglycaemia as a function of HbA1c in type 2 diabetes: Insulin glargine 300 U/mL in a patient-level pooled analysis of EDITION 1, 2 and 3.
Bonadonna RC; Yale JF; Brulle-Wohlhueter C; Boëlle-Le Corfec E; Choudhary P; Bailey TS
Diabetes Obes Metab; 2019 Mar; 21(3):715-719. PubMed ID: 30414260
[TBL] [Abstract][Full Text] [Related]
53. Titratable fixed-ratio combination of insulin glargine plus lixisenatide: A simplified approach to glycemic control in type 2 diabetes mellitus.
Giorgino F; Caruso I; Napoli R
Diabetes Res Clin Pract; 2020 Dec; 170():108478. PubMed ID: 33002548
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety of weight-based insulin glargine dose titration regimen compared with glucose level- and current dose-based regimens in hospitalized patients with type 2 diabetes: a randomized, controlled study.
Li X; Du T; Li W; Zhang T; Liu H; Xiong Y
Clin Ther; 2014 Sep; 36(9):1269-75. PubMed ID: 25062651
[TBL] [Abstract][Full Text] [Related]
55. Effectiveness and safety of insulin glargine 300 unit/mL in Japanese type 2 diabetes mellitus patients: a 12-month post-marketing surveillance study (X-STAR study).
Odawara M; Matsuhisa M; Hirose T; Koshida R; Senda M; Tanaka Y; Terauchi Y
Expert Opin Pharmacother; 2020 Oct; 21(14):1771-1780. PubMed ID: 32693663
[TBL] [Abstract][Full Text] [Related]
56. Comparison of Insulin Glargine 300 Units/mL and 100 Units/mL in Adults With Type 1 Diabetes: Continuous Glucose Monitoring Profiles and Variability Using Morning or Evening Injections.
Bergenstal RM; Bailey TS; Rodbard D; Ziemen M; Guo H; Muehlen-Bartmer I; Ahmann AJ
Diabetes Care; 2017 Apr; 40(4):554-560. PubMed ID: 28115474
[TBL] [Abstract][Full Text] [Related]
57. Switching from Neutral Protamine Hagedorn Insulin to Insulin Glargine 300 U/mL Improves Glycaemic Control and Reduces Hypoglycaemia Risk: Results of a Multicentre, Prospective, Observational Study.
Wolnik B; Wiza D; Szczepanik T; Syta A; Klupa T
J Diabetes Res; 2020; 2020():8751348. PubMed ID: 32337298
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of MK-1293 insulin glargine compared with originator insulin glargine (Lantus) in type 1 diabetes: A randomized, open-label clinical trial.
Home PD; Lam RLH; Carofano WL; Golm GT; Eldor R; Crutchlow MF; Marcos MC; Rosenstock J; Hollander PA; Gallwitz B
Diabetes Obes Metab; 2018 Sep; 20(9):2220-2228. PubMed ID: 29766635
[TBL] [Abstract][Full Text] [Related]
59. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.
Hurren KM; O'Neill JL
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1521-1526. PubMed ID: 27710135
[TBL] [Abstract][Full Text] [Related]
60. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
